Details of the Drug Combinations

General Information of This Drug (ID: DMD9RV3)

Drug Name
INCB039110   DMD9RV3
Synonyms Examlpe 294 [WO2011112662]
Indication
Disease Entry ICD 11 Status REF
Malignant neoplasm 2A00-2F9Z Phase 2 [1]
Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Everolimus + INCB039110 DCIKDJU Everolimus Classical Hodgkin Lymphoma [3]
INCB039110 + INCB24360 DCGSCH2 INCB24360 Solid Tumors [4]
INCB039110 + Osimertinib DCOXCM5 Osimertinib Lung Cancer [5]
INCB039110 + Ibrutinib DCTJ19B Ibrutinib Lymphoma [6]
Trametinib + INCB039110 DCSFEUK Trametinib Melanoma [7]
Erlotinib + INCB039110 DCPPCPS Erlotinib Solid Tumors and Hematologic Malignancy [8]
INCB039110 + Docetaxel DCG0YZE Docetaxel NSCLC (Non-small Cell Lung Carcinoma) [9]
Ruxolitinib + INCB039110 DCB1W4T Ruxolitinib MPN (Myeloproliferative Neoplasms) [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8364).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT03697408) Itacitinib + Everolimus in Hodgkin Lymphoma
4 ClinicalTrials.gov (NCT02559492) Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
5 ClinicalTrials.gov (NCT02917993) An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
6 ClinicalTrials.gov (NCT02760485) A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
7 ClinicalTrials.gov (NCT03272464) INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
8 ClinicalTrials.gov (NCT02355431) Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
9 ClinicalTrials.gov (NCT02257619) Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
10 ClinicalTrials.gov (NCT03144687) A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis